GLP-1 for Obesity

Obesity is a chronic, complex disease defined by excess body fat that impairs health. In the United States, roughly 42% of adults meet the clinical definition (BMI ≥30 kg/m²), and more than 2 billion people worldwide are affected. Far from a personal failing, obesity involves a persistent dysregulation of energy balance driven by genetics, hormones, the food environment, sleep, stress, and socioeconomic factors. The World Health Organization classifies it as a noncommunicable disease requiring long-term medical management.

The health consequences are wide-ranging. Obesity raises the risk of type 2 diabetes, cardiovascular disease, obstructive sleep apnea, nonalcoholic fatty liver disease (MASLD), osteoarthritis, and several cancers. It shortens life expectancy and lowers quality of life, yet historically it has been treated as though it were simply a matter of willpower. This mischaracterization has contributed to decades of undertreated disease.

Physiology helps explain why diet and exercise alone so often fail in the long run. The body defends its current weight through compensatory changes in appetite hormones, metabolic rate, and neural reward signaling. GLP-1 receptor agonists — and the newer dual GLP-1/GIP agonists — are the first medications to harness these pathways effectively, producing sustained, clinically meaningful weight loss that was previously achievable only through bariatric surgery.

GLP-1 (glucagon-like peptide-1) is a hormone secreted by the gut in response to food. It acts on the hypothalamus to suppress appetite, slows gastric emptying to prolong satiety, and reduces cravings. Pharmaceutical GLP-1 receptor agonists mimic and amplify this signal at doses higher than physiological levels, producing a consistent reduction in caloric intake without requiring deliberate dietary restraint. Tirzepatide adds activation of the GIP receptor, which appears to further enhance fat-tissue remodeling and metabolic effects.

The STEP-1 trial (Wilding et al., N Engl J Med 2021 [1]) enrolled 1,961 adults with obesity or overweight plus a weight-related comorbidity, none with diabetes. After 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg, participants lost a mean of 14.9% of body weight versus 2.4% with placebo. Notably, 69.1% of participants on semaglutide lost at least 10% of their baseline weight, 50.5% lost at least 15%, and 32% lost at least 20% — outcomes that had previously required bariatric surgery for most patients.

SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022 [2]) tested tirzepatide, a dual GLP-1/GIP receptor agonist, in 2,539 adults over 72 weeks. At the highest dose (15 mg), participants lost a mean of 20.9% of body weight versus 3.1% with placebo. Among those on the 15-mg dose, 63% achieved at least 20% weight loss and 57% lost at least 22.5%. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023. The earlier SCALE trial (Pi-Sunyer et al., N Engl J Med 2015 [3]) established liraglutide 3.0 mg (Saxenda) as the first GLP-1 approved for obesity, with a mean 8.4% weight loss versus 2.8% with placebo over 56 weeks in 3,731 adults.

Behavioral therapy enhances outcomes. STEP-3 (Wadden et al., JAMA 2021 [4]) combined semaglutide 2.4 mg with a low-calorie diet and intensive behavioral counseling, achieving a mean 16.0% weight loss versus 5.7% with placebo plus intensive counseling. SURMOUNT-3 (Wadden et al., Nat Med 2023 [5]) randomized participants who had already lost a median of 6.9% of body weight during a 12-week intensive lifestyle lead-in, then added tirzepatide or placebo for 72 weeks. Tirzepatide produced an additional 18.4% weight reduction, versus 2.5% with placebo, for a total loss from baseline of approximately 24.5% — demonstrating that drug and lifestyle interventions are additive, not interchangeable.

Both Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults with an initial BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher plus at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Saxenda (liraglutide 3.0 mg) carries the same BMI thresholds. All are intended as adjuncts to a reduced-calorie diet and increased physical activity, not as standalone treatments.

Clinicians weigh several contraindications before prescribing. GLP-1 receptor agonists carry an FDA black-box warning regarding medullary thyroid carcinoma and should not be used by patients with a personal or family history of that cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2). A history of pancreatitis warrants caution. These medications are not recommended during pregnancy. Patients who also have type 2 diabetes may instead be prescribed lower-dose formulations of semaglutide (Ozempic) or tirzepatide (Mounjaro) that address both glucose control and weight.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually worst during dose escalation and tend to improve over weeks. Serious but uncommon adverse events include acute pancreatitis, cholelithiasis, and a modest increase in resting heart rate. The black-box warning about thyroid C-cell tumors is based on rodent data; no increased incidence has been confirmed in human trials to date, but patients with relevant personal or family history should not use these medications.

Weight regain is a clinically important reality. The STEP-1 extension study (Wilding et al., Diabetes Obes Metab 2022 [6]) followed participants one year after stopping semaglutide: they regained approximately two-thirds of the weight lost during treatment, and improvements in cardiometabolic markers largely reversed. This underscores that obesity is a chronic condition requiring long-term management, and that GLP-1 medications are most effective when maintained alongside sustained dietary and activity changes. Cost, insurance coverage gaps, and supply constraints remain significant access barriers for many patients.